DPHARM 2023: Accelerating Clinical Trial Enrollment

Colleen Hoke Speaking

Following an introduction from Hoke, O’Rourke emphasized the impact of the solutions on the company’s own clinical trial sites. “This year, these have gone a long way in accelerating trials within our own sites, enabling transparency to our sponsors,” he said. ObjectiveHealth began offering them as solutions outside of its own site network in 2023.

ObjectiveScreen is the company’s artificial intelligence-recruitment tool. Rather than working off of social media or online campaigns, it is embedded into coordinators’ workflows at the company’s sites. It syncs with the electronic health care systems and uses machine learning to identify candidates as they are visiting the practice.

As a result, the solution enables patients to be identified “on-the-fly” as they come into the practice.

ObjectiveView is designed for sponsors. It works hand-in-hand with ObjectiveScreen to offer a real-time view into the total eligible recruitment funnel for all enrollment activities. Sponsors are given full access to the data, with which they can create criteria as they see fit for their study.

The real-world case study presented was from ObjectiveHealth’s own sites and a nonalcoholic steatohepatitis (NASH) trial that is currently ongoing. Following intervention from ObjectiveScreen, which included machine learning for NASH risk, (one of the major therapeutic areas that ObjectiveHealth targets), rules-based matching for criteria, and optimized patient prioritization for targeted recruitment, the number of eligible patients increased from 12.5% to 46.4%. A jump in screened patients occurred from 19.9% to 51.2%, enrollment rate increased from 10.9% to 23.1%, and screen fail rate dropped from 89.1% to 76.9%. These changes occurred over the span of 8 weeks.